Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Dabrafenib btd date 2023?What is dabrafenib mesylate msn patent issue?Abbvie humira patent cliff navigation success?How might diet alleviate lipitor's liver impact?Are there income restrictions for lipitor's patient program?
See the DrugPatentWatch profile for Argatroban
Argatroban is an anticoagulant in the direct thrombin inhibitor (DTI) drug class. It works by directly inhibiting thrombin (factor IIa), which helps prevent clot formation and clot extension. [1]
Heparins (like unfractionated heparin and low-molecular-weight heparins) primarily enhance antithrombin activity, while argatroban inhibits thrombin directly as a small-molecule drug. This direct mechanism is why DTIs like argatroban are used when thrombin inhibition is needed and heparin is not appropriate. [1]
Argatroban is commonly used in the setting of heparin-induced thrombocytopenia (HIT) as an alternative anticoagulant. [1]
Argatroban is sold under the brand name Argatroban Injection. [1]
As a direct thrombin inhibitor, argatroban dosing typically requires laboratory monitoring of anticoagulant effect, commonly using activated partial thromboplastin time (aPTT) to guide dose adjustments. [1] Sources: [1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=19143
Other Questions About Argatroban :